XML 31 R32.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Share-Based Compensation - Schedule of Share-Based Compensation Recognized in Consolidated Statements of Income and Comprehensive Income (Detail) (USD $) In Thousands, unless otherwise specified | 3 Months Ended | 6 Months Ended
--- | --- | ---
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2014 | Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] |  |  |  |
Total share-based compensation expense | $ 12,147 us-gaap_AllocatedShareBasedCompensationExpense | $ 6,857 us-gaap_AllocatedShareBasedCompensationExpense | $ 19,028 us-gaap_AllocatedShareBasedCompensationExpense | $ 13,792 us-gaap_AllocatedShareBasedCompensationExpense
Molecular Diagnostic Testing Expense |  |  |  |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] |  |  |  |
Total share-based compensation expense | 249 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = mygn_CostOfMolecularDiagnosticTestingMember | 209 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = mygn_CostOfMolecularDiagnosticTestingMember | 447 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = mygn_CostOfMolecularDiagnosticTestingMember | 432 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = mygn_CostOfMolecularDiagnosticTestingMember
Pharmaceutical and Clinical Services Expense |  |  |  |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] |  |  |  |
Total share-based compensation expense | 123 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = mygn_CostOfPharmaceuticalAndClinicalServicesMember | 74 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = mygn_CostOfPharmaceuticalAndClinicalServicesMember | 283 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = mygn_CostOfPharmaceuticalAndClinicalServicesMember | 137 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = mygn_CostOfPharmaceuticalAndClinicalServicesMember
Research And Development Expense |  |  |  |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] |  |  |  |
Total share-based compensation expense | 1,252 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = us-gaap_ResearchAndDevelopmentExpenseMember | 846 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = us-gaap_ResearchAndDevelopmentExpenseMember | 2,017 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = us-gaap_ResearchAndDevelopmentExpenseMember | 1,627 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = us-gaap_ResearchAndDevelopmentExpenseMember
Selling, General, and Administrative Expenses |  |  |  |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] |  |  |  |
Total share-based compensation expense | $ 10,523 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = us-gaap_SellingGeneralAndAdministrativeExpensesMember | $ 5,728 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = us-gaap_SellingGeneralAndAdministrativeExpensesMember | $ 16,281 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = us-gaap_SellingGeneralAndAdministrativeExpensesMember | $ 11,596 us-gaap_AllocatedShareBasedCompensationExpense / us-gaap_IncomeStatementLocationAxis = us-gaap_SellingGeneralAndAdministrativeExpensesMember

X
- Definition Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.F) -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section F + Details
Name: | us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=mygn_CostOfMolecularDiagnosticTestingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=mygn_CostOfPharmaceuticalAndClinicalServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |